Combines phentermine (appetite suppressant) with topiramate (antiepileptic) to reduce hunger and enhance satiety through complementary mechanisms European Medicines Agency refused marketing authorisation citing cardiovascular safety, psychiatric adverse effects, cognitive impairment, and teratogenic risks Clinical trials showed 911% mean weight loss at one year, but no head-to-head comparisons with UK-licensed medications or cardiovascular outcomes trials exist Contraindicated in pregnancy due to significant risk of orofacial clefts
Wegovy is contraindicated with a personal/family history of medullary thyroid carcinoma (MTC) or MEN 2
Later in 2023, a multisociety statement from gastroenterology and hepatology organizations, including the AGA, AASLD, ACG, ASGE, and NASPGHAN, advised against routine discontinuation and emphasized individualized risk assessment [9]
Behavioral observations For experiment 1: Antagonism of serotonergic behavior induced by the 5-HT 1A -receptor agonist ()-8-OH-DPAT: Dose response and efficacy of oral treatment with Atlas987 rats were placed in the observation cage immediately after treatment with () - 8-OH-DPAT and their behavior was scored for 60 min
The medication is an investigational once-daily oral GLP-1 receptor agonist designed to help people lose weight and improve blood sugar control